Contrasting Edwards Lifesciences (NYSE:EW) and Vasamed (OTCMKTS:VSMD)

Edwards Lifesciences (NYSE:EW) and Vasamed (OTCMKTS:VSMD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Insider & Institutional Ownership

79.5% of Edwards Lifesciences shares are held by institutional investors. 0.3% of Edwards Lifesciences shares are held by insiders. Comparatively, 8.0% of Vasamed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Edwards Lifesciences has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Vasamed has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Edwards Lifesciences and Vasamed, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	0	8	16	3	2.81
Vasamed	0	0	0	0	0.00

Edwards Lifesciences presently has a consensus target price of $96.39, suggesting a potential upside of 2.20%. Given Edwards Lifesciences’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Edwards Lifesciences is more favorable than Vasamed.

Profitability

This table compares Edwards Lifesciences and Vasamed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	17.39%	15.19%	11.71%
Vasamed	N/A	N/A	N/A

Valuation and Earnings

This table compares Edwards Lifesciences and Vasamed”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$6.07 billion	8.95	$1.07 billion	$1.88	50.17
Vasamed	N/A	N/A	N/A	N/A	N/A

Edwards Lifesciences has higher revenue and earnings than Vasamed.

Summary

Edwards Lifesciences beats Vasamed on 10 of the 11 factors compared between the two stocks.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

About Vasamed

Vasamed Incorporated designs, licenses, manufactures, and distributes products, software, and services for assessing and managing hemodynamic health in the United States. It offers SensiLase PAD-IQ, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation for Doppler-obtained pressures; and Wound Imaging & SmartDraw wound measurement systems. The company also provides PAD-IQ Studycast that provides rapid transmission of diagnostic tests to vascular specialist for interpretation of results and medically indicated therapeutic intervention; and custom carrying case to secure and protect the PAD-IQ system. It serves clinicians and patients. The company was founded in 1988 and is headquartered in Eden Prairie, Minnesota.